Immorta Bio Presents SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting

PR Newswire

May 5, 2025

Immorta Bio was selected to present alongside Pfizer and the University of Pittsburgh at the 2025 American Association of Immunologists Annual Meeting in Honolulu. The company unveiled new data on SenoVax™, its first-in-class senolytic immunotherapy that trains the immune system to target senescent cells—offering a novel approach to treating both cancer and aging.

‍

Read Full Article

Explore More

October 24, 2025

Immorta Bio Presents SenoVax™ Cancer Senolytic Immunotherapy Preclinical Data at American Association of Immunologists Meeting

Never Miss A Headline.

Subscribe to Immorta Bio's Newsletter

Explore More

Immorta Bio's Newest IP + Preclinical Progress: Advancing Mitochondrial Regeneration Strategy

Immorta Bio’s Research Points to a Potential Pathway Toward "Re-Awakening" Coma Patients

Immorta Bio Reports Activity of SenoVax™ in CTE Model